CD19
E1188119
UNEXPLORED
CD19 is a B-cell surface protein widely used as a key immunotherapy target in treatments for B-cell malignancies such as certain leukemias and lymphomas.
All labels observed (1)
| Label | Occurrences |
|---|---|
| CD19 canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T15983058 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: CD19 Context triple: [Juno Therapeutics, therapeuticTarget, CD19]
-
A.
CD22
CD22 is a B-cell–specific surface glycoprotein that functions as an inhibitory co-receptor modulating B cell receptor signaling and immune responses.
-
B.
CD21
CD21 is a complement receptor (CR2) found on B cells and follicular dendritic cells that plays a key role in B cell activation and the immune response.
-
C.
CD20 protein
CD20 protein is a cell-surface antigen found primarily on B lymphocytes and is a key therapeutic target in certain autoimmune diseases and B-cell malignancies.
-
D.
CD46
CD46 is a human cell-surface complement regulatory protein that also serves as an entry receptor for various pathogens, including certain adenoviruses and measles virus.
-
E.
CD38
CD38 is a cell surface glycoprotein with ectoenzyme and receptor functions, highly expressed on plasma cells and targeted in therapies for multiple myeloma and other hematologic malignancies.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: CD19 Target entity description: CD19 is a B-cell surface protein widely used as a key immunotherapy target in treatments for B-cell malignancies such as certain leukemias and lymphomas.
-
A.
CD22
CD22 is a B-cell–specific surface glycoprotein that functions as an inhibitory co-receptor modulating B cell receptor signaling and immune responses.
-
B.
CD21
CD21 is a complement receptor (CR2) found on B cells and follicular dendritic cells that plays a key role in B cell activation and the immune response.
-
C.
CD20 protein
CD20 protein is a cell-surface antigen found primarily on B lymphocytes and is a key therapeutic target in certain autoimmune diseases and B-cell malignancies.
-
D.
CD46
CD46 is a human cell-surface complement regulatory protein that also serves as an entry receptor for various pathogens, including certain adenoviruses and measles virus.
-
E.
CD38
CD38 is a cell surface glycoprotein with ectoenzyme and receptor functions, highly expressed on plasma cells and targeted in therapies for multiple myeloma and other hematologic malignancies.
- F. None of above. chosen
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.